| Market Cap | 1.31B | P/E | - | EPS this Y | 68.60% | Ern Qtrly Grth | - |
| Income | -145.93M | Forward P/E | -12.87 | EPS next Y | 51.40% | 50D Avg Chg | -9.00% |
| Sales | 382.24M | PEG | -0.47 | EPS past 5Y | - | 200D Avg Chg | -27.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 44.80% | 52W High Chg | -55.00% |
| Recommedations | 1.90 | Quick Ratio | 2.64 | Shares Outstanding | 206.89M | 52W Low Chg | 3.00% |
| Insider Own | 1.15% | ROA | -6.91% | Shares Float | 192.19M | Beta | 1.88 |
| Inst Own | 86.61% | ROE | - | Shares Shorted/Prior | 24.06M/24.38M | Price | 6.95 |
| Gross Margin | 47.06% | Profit Margin | -38.18% | Avg. Volume | 2,556,691 | Target Price | 14.45 |
| Oper. Margin | 8.01% | Earnings Date | Oct 31 | Volume | 5,164,701 | Change | -0.29% |
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| JMP Securities | Market Outperform | Aug 6, 24 |
| Barclays | Equal-Weight | Aug 6, 24 |
| RBC Capital | Outperform | Aug 6, 24 |
| HC Wainwright & Co. | Buy | Aug 6, 24 |
| JMP Securities | Market Outperform | May 7, 24 |
| HC Wainwright & Co. | Buy | May 7, 24 |
| Needham | Buy | May 7, 24 |
| Needham | Buy | Apr 10, 24 |
| Needham | Buy | Jan 8, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stonehouse Jon P | President & CEO President & CEO | Feb 01 | Sell | 10.38 | 100,000 | 1,038,000 | 1,008,739 | 02/02/23 |
| Stonehouse Jon P | President & CEO President & CEO | Feb 01 | Option | 5.45 | 100,000 | 545,000 | 1,108,739 | 02/02/23 |
| LEE KENNETH B JR | Director Director | Jan 31 | Option | 1.71 | 15,000 | 25,650 | 52,118 | 02/02/23 |
| Sheridan William P | Chief Medical Office.. Chief Medical Officer | Mar 10 | Option | 3.22 | 148,302 | 477,532 | 199,093 | 03/14/22 |
| Sheridan William P | Chief Medical Office.. Chief Medical Officer | Mar 10 | Sell | 17.26 | 161,139 | 2,781,259 | 37,954 | 03/14/22 |
| Jones Michael L | Exec. Director, Fina.. Exec. Director, Finance - PAO | Mar 01 | Option | 4.73 | 2,300 | 10,879 | 13,498 | 03/03/22 |
| Jones Michael L | Exec. Director, Fina.. Exec. Director, Finance - PAO | Mar 01 | Sell | 17.2 | 2,300 | 39,560 | 11,198 | 03/03/22 |
| Stonehouse Jon P | President & CEO President & CEO | Jan 11 | Option | 4.73 | 184,000 | 870,320 | 1,085,602 | 01/13/22 |
| Stonehouse Jon P | President & CEO President & CEO | Jan 11 | Sell | 15.04 | 184,000 | 2,767,360 | 901,602 | 01/13/22 |
| Sheridan William P | Chief Medical Office.. Chief Medical Officer | Jun 01 | Option | 5.26 | 163,573 | 860,394 | 106,289 | 06/01/21 |
| Sheridan William P | Chief Medical Office.. Chief Medical Officer | Jun 01 | Sell | 15.01 | 163,573 | 2,455,231 | 14,475 | 06/01/21 |
| Barnes Alane P | Senior VP, Chief Leg.. Senior VP, Chief Legal Officer | Dec 15 | Option | 4.15 | 13,741 | 57,025 | 121,802 | 12/15/20 |